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such as with tetramer staining, intracellular cytokine
staining, and degranulation assays, are becoming
more readily available and allow us to functionally
interrogate lymphocyte subpopulations. These assess-
ments, if validated as predictors of infection and
relapse, will not only help elucidate the impact of
various graft-intrinsic and extrinsic factors on the
kinetics of immune recovery, but may also help us
identify those patients at highest risk for these compli-
cations.
The article by Jacobson et al. [4] challenges us
further to identify what factor or factors may be re-
sponsible for the apparent delay in adaptive immunity
observed in their patients undergoing UCB trans-
plantation. The tools now exist to better assess im-
mune function and perhaps overcome this brick
wall, previously limiting our ability to understand
the myriad of factors negatively influencing immune
reconstitution. What are ‘‘brick walls’’ anyway? As
we are told by Randy Pausch in The Last Lecture,
‘‘Brick walls . are there to give us a chance to
show how badly we want something . brick walls
are there to stop the other people!’’ [Not us!] It’s
time to remove this wall and finally figure out how to
enhance the pace of immune reconstitution . and
win the race.’’From the Fred Hutchinson Cancer Research Center, Seattle,
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Effie W. PetersdorfThe MHC is home to a series of genes that have
highly coordinated functions in the immune response.
Genes involved in antigen presentation (HLA-A, C, B,
DR, DQ, and DP) reside near genes involved in anti-
gen processing (TAP), the innate response (MICA,
MICB), stress and inflammation (TNF, LTA, LST),
and regulatory receptors (NOTCH4). Although the
class I, III, and II regions are each distinguished by
their unique genetic landscape, variation across the
MHC is highly organized into haplotypes that linkgenes from the extended class I through to the ex-
tended class II region.
Much like a patchwork quilt where individual
blocks can be configured in different ways to create
unique patterns, the MHC has segments or blocks of
highly conserved sequences that are characteristic of
haplotypes. A key to understanding the MHC is the
nature of its ‘‘blockiness’’ and haplotypic associations.
The study by Bettens et al. [1] examined 2 genes that
reside in distinct regions of the MHC and their role
in transplantation outcome: the TNF segment in the
class III region, and HLA-DP in class II.
At the centromeric end of the HLA region resides
HLA-DP, a highly polymorphic locus (over 152
unique alleles recognized as of January 2012; http://
www.ebi.ac.uk/imgt/hla/) that is firmly established as
a classical transplantation locus [2,3]. Although
donor matching is associated with a lower risk of
graft-versus-host disease (GVHD), practically, pro-
spective donor matching is difficult because of the
weaker linkage disequilibrium that leads to mismatch
Biol Blood Marrow Transplant 18:493-496, 2012 495Of Genes, Blocks, and Haplotypesrates in excess of 80% in otherwise HLA-A, C, B, DR,
and DQ-matched patients and donors.
Telomeric toHLA-DP is class III, a region that en-
codes a family of genes known as the ‘‘TNFblock.’’ This
7-kb region contains TNF-a, TNF-b (lymphocytoxin-
a, LTA), leucocyte-specific transcript-1 (LST1), and
allograft inflammatory factor (AIF). The best known,
TNF-a, is a pro-inflammatory cytokine produced
by macrophages, monocytes, natural killer cells, and
T cells. In transplantation, TNF plays a critical role in
the first phase of GVHD involving activation of
antigen-presenting cells, enhancement of alloantigen
presentation, and induction of additional inflammatory
cytokines that lead to the recruitment of effector cells,
whichmediate target organ damage [4]. LST1 is a factor
linked to inflammation in autoimmunity [5].
TNF block content, organization, and linkage dis-
equilibrium of HLA-A, B, and DR haplotypes have
been extensively studied using microsatellite and sin-
gle nucleotide polymorphism (SNP) markers [6,7].
The TNFd microsatellite, located in the intronic
region of LST1, has at least 6 known alleles of which
the d3 and d4 alleles correlate with higher TNF
production and risk of GVHD. SNP analysis has
uncovered polymorphism in the 50 promoter region
of TNF-a, which defines allele-specific expression.
TNFd and TNF-a promoter SNP haplotypes show
variation in ethnically diverse populations [6,7]. The
specific TNF content of extended HLA haplotypes
may help explain why outcomes after transplantation
are not homogeneous among patients with leukemia
or myelodysplastic syndrome; at-risk or protective var-
iants may be linked to specific HLA haplotypes that
occur at higher frequency in some blood disorders
compared with others [8].
So what do HLA-DP and TNF have to do with
one another? In the study by Bettens et al. [1], the clin-
ical significance of microsatellite polymorphisms
within the TNF block and HLA-DPB1 patient-donor
mismatching were retrospectively examined in 246
patients who received an HLA-A, C, B, DRB1, or
DQB1 allele matched unrelated donor. The patients
and donors were typed for HLA-DPB1 alleles and
for 6 microsatellite markers within the TNF block.
The study addressed 3 major questions: (1) the
association of donor-patient mismatching for
DPB1 alleles and outcome; (2) the association of TNF
donor alleles to outcome, and (3) the combined effects
of HLA-DP mismatching and donor TNF genotype.
They found that the classical definition of patient-
donor DPB1 mismatching correlated with higher
mortality. Furthermore, patients who underwent trans-
plantation from donors positive for TNFd4/d5 micro-
satellite alleles had higher mortality compared with
patients undergoing transplantations from d4/d5-
negative donors. Importantly, patients who were
transplanted from TNFd4/d5-positive and HLA-DPmismatched donors had the highest risk of mortality,
suggesting additive dose effects. These data point to
a role for LST1 (TNFd) in transplantation outcome
and the consequences of cumulative effects of genes
linked on the same extended HLA haplotype.
The Bettens analysis opens up several new areas of
study. The positive linkage disequilibrium between
TNFd and TNF-a [6,7] suggests that the TNF
block contains at least 2 potential determinants for
transplantation outcome. Elucidation of the specific
pathways and gene-gene interactions will be important
for understanding the mechanisms that lead to inflam-
mation. In this regard, the functional consequences of
haplotypic variation on TNF expression and alterna-
tive splicing of LCT1 [9] take on new meaning in
HLA-associated disease.
How can the new information onTNFd andDPB1
be used to benefit patients? Prospective donor typing
for the TNF block andHLA-DPB1 could aid in lower-
ing the risks to patients.Donorswho are d4/d5-negative
and HLA-DPB1-matched are desirable, whereas d4/
d5-postive HLA-DPB1-mismatched donors should be
avoided if possible. Unknown is the potential benefit
of extending a search if the initial search yields only
high-risk donors. To address this question, more infor-
mation is needed on the frequency of TNF block poly-
morphisms and their linkage on HLA haplotypes,
particularly in ethnically diverse populations [6,7], for
estimating the likelihood of finding d4/d5-negative,
HLA-DPB1-matched donors for a given patient.
Finally, the association of TNF receptor II with clinical
outcome highlights a need to better understand ligand-
receptor interactions [10]. TNF-a blockade has been
successfully used to treat acute GVHD [11-13].
Knowledge of the patient and donor’s HLA-DP and
TNF block genotypes offers a promising approach for
individualized treatment of patients at high risk of
GVHD complications and for monitoring patients
whose haplotypes place them at particularly high risk
after transplantation. What might the future hold? It
might all depend on how blocky one is.ACKNOWLEDGMENT
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